| Title： | Guidelines for schizophrenia Prevention and Treatment in China |
| Edition： | Updated |
| Classification： | Standard guideline |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | |
| Evidence classification method： | The GRADE method was used to evaluate the evidence quality of the result tables. According to the GRADE , the quality of evidence was classified into four levels: high, medium, low, and very low. Five de-escalation factors – risk of bias, imprecision, inconsistency, indirectness, and publication bias – and three escalation factors – large effect sizes, dose-response relationships, and possible confounding factors were considered as appropriate (negative bias) in the evidence grading process. Upon completion of the evidence grading, the evidence will be presented via an evidence summary table. In summarizing and presenting the evidence for each clinical question, the guideline development group used the GRADEpro guideline development tool (i.e. www.gradepro.org ), to construct a GRADE evidence summary and a framework of "evidence to decision" (EtD) to summarize the results of systematic reviews 13 – 15. The EtD tables corresponding to each clinical question include the following: Effectiveness and safety related to interventions and controls, health resource utilization, cost-effectiveness, patient values and preferences, impact on health equity, acceptability, and feasibility sections. |
| Development unit： | Psychiatry Society of Chinese Medical Association |
| Registration time: | 2023-03-28 |
| Registration number： | PREPARE-2023CN195 |
| Purpose of the guideline: |
Latest registration
